FDA Approved: RYALTRIS — Supplemental Application (HIKMA SPECIALTY USA INC.)

View source ↗

Summary

FDA approved a supplemental application for RYALTRIS (olopatadine hydrochloride and mometasone furoate) submitted by Hikma Specialty USA Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis
• Allergic Rhinitis

Drugs mentioned

• RYALTRIS (OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE)

Snippet

SUPPL AP for RYALTRIS (OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE)